Discuss the data presented at EHA 2024 on the efficacy and safety of teclistimab in patients with relapsed/refractory multiple myeloma (RRMM) with high-risk features: a subgroup analysis of the phase 1/2 MajesTEC-1 study. (Abstract)
1. What was the objective of the subgroup analysis of this study?
2. How was this study designed/what methodology was used?
3. What results were presented?
  1. N=165
4. N=24 aged ≥75 years
5. N=20 ISS stage III
6. N=38 high-risk cytogenetics
7. N=28 extramedullary disease
8. N=18 bone marrow plasma cells
9. N=50 penta-drug refractory
  1. Median follow up ~30 months across subgroups
  2. Objective Response Rate (ORR)
  3. Median duration of response (mDOR)
  4. Safety

Top 5 Multiple Myeloma Content of 2024

December 24th 2024

Article

Through interviews and articles infused with expert insight, progress against this cancer that develops in the bone marrow was showcased.

ICYMI: Highlights From ASCO 2024

December 21st 2024

Article

Top coverage from the 2024 American Society of Clinical Oncology (ASCO) annual meeting included research topics in non-small cell lung cancer (NSCLC), multiple myeloma, metastatic colorectal cancer (mCRC), and more.

ICYMI: Highlights From SLEEP 2024

December 18th 2024

Article

Check out our top 5 most-viewed pieces of coverage from the 2024 SLEEP meeting.

ICYMI: Highlights From IMS 2024

December 17th 2024

Article

The expert knowledge presented at this year’s International Myeloma Society (IMS) annual meeting focused on minimal residual disease testing and status, defining and treating high-risk disease, CEPHEUS trial findings, and an investigational off-the-shelf chimeric antigen receptor T-cell therapy.